Cargando…
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis
Osteoporosis and osteoporosis-related fractures are growing problems with the aging population and are associated with significant morbidity and mortality. At this time, other than parathyroid hormone analogs, all therapies for osteoporosis are antiresorptive. Therefore, researchers have focused eff...
Autores principales: | Shah, Arti D, Shoback, Dolores, Lewiecki, E Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459616/ https://www.ncbi.nlm.nih.gov/pubmed/26082665 http://dx.doi.org/10.2147/IJWH.S73244 |
Ejemplares similares
-
Sclerostin Inhibition in the Management of Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2016) -
Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis
por: Aditya, Suruchi, et al.
Publicado: (2021) -
Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
por: Lewiecki, E Michael
Publicado: (2010) -
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2009) -
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges
por: MacNabb, Claire, et al.
Publicado: (2016)